Safety and Efficacy Study of Dysport RU and Glabellar Lines
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
The primary objective is to assess the dose response versus placebo of a single treatment of
Dysport RU (Dysport RU, Ready to Use, for injection), for the improvement in appearance of
moderate to severe glabellar lines at maximum frown.
Phase:
Phase 2
Details
Lead Sponsor:
Ipsen
Treatments:
abobotulinumtoxinA Botulinum Toxins Botulinum Toxins, Type A incobotulinumtoxinA onabotulinumtoxinA